The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus

<div>The level of plasma ANGPTL3 after metformin or canagliflozin treatment. The change of plasma ANGPTL3 level in patients with type 2 diabetes mellitus before and after treatment.</div>

Journal of Diabetes Research

fig2

Figure 2

Figure 2: The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus 